Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study With Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit From Continued Treatment

NCT07444567 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07444567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07444567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study With Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
July 24, 2026
Completion date
December 27, 2029
Enrollment
230 (estimated)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

asthma, eosinophilic granulomatosis with polyangiitis (egpa), hypereosinophilic syndrome (hes)